Definitive Contract HHSN272201800012C
Award Date
4/1/18
Potential Completion Date
9/30/23
Potential Value
$5.6M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Innovation Pathways, LLC
Ultimate Awardee
Not listed
NAICS Category
541713 - Research and Development in Nanotechnology
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Palo Alto, CA 94301, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
12
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $4,499,688.00 cost-plus-fixed-fee definitive contract with Innovation Pathways, LLC to support the pharmacological development of IPW-5371 fumarate as a radiation medical countermeasure for the treatment of delayed radiation lung injury. The contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and is not a set-aside. The contract was sourced from a Broad Agency Announcement (BAA) seeking proposals...
<p>The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases (HHS-NIH-NIAID) awarded a $5.2 million delivery order contract to Alpha Genesis Inc. to provide maintenance of specific pathogen-free macaque breeding colonies in Yemassee, South Carolina from September 30, 2022 through September 29, 2024. The cost plus fixed fee contract supports NIAID research requiring non-human primates through care of the macaque colonies.</p>
The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $4.4 million delivery order contract to Alpha Genesis Inc. to provide maintenance services for specific pathogen free macaque breeding colonies through September 2024. Under the cost-plus-fixed-fee contract held by Alpha Genesis, the company will support NIAID's research efforts by caring for primate subjects at its facility in Yemassee, South Carolina. No subcontractors or set aside...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $12,085,422.00 cost plus fixed fee delivery order contract to Sri International of West Menlo Park, California to perform animal model development and efficacy testing from September 19, 2022 through September 29, 2026. A subcontract valued at an undisclosed amount was also awarded to The Medical College of Wisconsin, Inc. to conduct a non-good laboratory...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $3,225,000 cost-plus-fixed-fee delivery order contract to Alpha Genesis Inc. to provide maintenance of National Institute of Allergy and Infectious Diseases (NIAID) specific pathogen-free macaque breeding colonies. The contract has a completion date of June 17, 2021 and a potential value of $3,224,999.62. Alpha Genesis Inc. is a for-profit Subchapter S...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $9,374,351.00 cost-plus-fixed-fee delivery order contract to Sri International, a non-profit research institute, for animal model development and initial efficacy testing of radiation/nuclear medical countermeasure (MCM) products. The contract does not have a set-aside designation and is scheduled to be completed by December 10, 2021. Sri International has...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a firm-fixed-price definitive contract valued at $585,999.00 to Protein Innovation Labs, Inc., a small business concern, for the provision of reagents to support immunologic analysis of non-mammalian models. This contract was awarded under the National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC) Small Business Innovation...
This federal contract award is for a Delivery Order under the National Institute of Allergy and Infectious Diseases (NIAID) Animal Models of Infectious Diseases 2010-2017 Indefinite Delivery, Indefinite Quantity (IDIQ) contract. The $1,513,255.77 cost-plus-fixed-fee contract was awarded to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a subsidiary of Lovelace Biomedical Research Institute, to provide a non-human primate model for testing the immunogenicity and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $31,725,938.61 cost-plus-fixed-fee contract to Revagenix Inc. to select a novel small molecule antibiotic for clinical development and advance it through IND filing and Phase 1 clinical studies. This contract was not set aside and has an ultimate completion date of August 31, 2026. The contract originated from a NIAID Broad Agency Announcement seeking proposals to develop medical countermeasures to mitigate and/or...
This is a federal contract award issued by the Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases to Battelle Memorial Institute, doing business as Battelle, a nonprofit research and development organization. The award, valued at $2,682,797.00, is a delivery order under the NIAID Preclinical Models of Infectious Diseases 2017-2024 indefinite delivery/indefinite quantity (IDIQ) contract vehicle. The work is for pre-clinical...